|
|
2015 Featured Talks » Development of Next Generation Angiogenesis Inhibitors
Charles Theuer, part 1 from MCC Industry Relations on Vimeo.
Charles Theuer, part 2 from MCC Industry Relations on Vimeo.
Charles Theuer, MD, PhD
President and CEO
TRACON Pharmaceuticals
Dr. Theuer has served as President and CEO of TRACON since July 2006. From 2004 to 2006, Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Prior to joining TargeGen, Dr. Theuer was Director of Clinical Oncology at Pfizer. At Pfizer, Dr. Theuer led the clinical development of Sutent® in kidney cancer; Sutent was approved by the U.S. FDA in 2006 for the treatment of advanced kidney cancer. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals and at the National Cancer Institute. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer’s previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, and gastrointestinal cancer epidemiology.
|
